title: Interaction of Lp(a) with plasminogen binding sites on cells.
abstract: Lp(a) competes with plasminogen for binding to cells but it is not known whether this competition is due to the ability of Lp(a) to interact directly with plasminogen receptors. In the present study, we demonstrate that Lp(a) can interact directly with plasminogen binding sites on monocytoid U937 cells and endothelial cells. The interaction of Lp(a) with these sites was time dependent, specific, saturable, divalent ion independent and temperature sensitive, characteristics of plasminogen binding to these sites. The affinity of plasminogen and Lp(a) for these sites also was similar (Kd = 1-3 microM), but Lp(a) bound to fewer sites (approximately 10-fold less). Both gangliosides and cell surface proteins with carboxy-terminal lysyl residues, including enolase, a candidate plasminogen receptor, inhibited Lp(a) binding to U937 cells. Additionally, Lp(a) interacted with low affinity lipoprotein binding sites on these cells which also recognized LDL and HDL. The ability of Lp(a) to interact with sites on cells that recognize plasminogen may contribute to the pathogenetic consequences of high levels of circulating Lp(a).
authors.affiliation: Department of Vascular Biology, Scripps Research Institute, La Jolla, CA, USA.
authors.forename: L A
authors.initials: LA
authors.lastname: Miles
authors.forename: G M
authors.initials: GM
authors.lastname: Fless
authors.forename: A M
authors.initials: AM
authors.lastname: Scanu
authors.forename: P
authors.initials: P
authors.lastname: Baynham
authors.forename: M T
authors.initials: MT
authors.lastname: Sebald
authors.forename: P
authors.initials: P
authors.lastname: Skocir
authors.forename: L K
authors.initials: LK
authors.lastname: Curtiss
authors.forename: E G
authors.initials: EG
authors.lastname: Levin
authors.forename: J L
authors.initials: JL
authors.lastname: Hoover-Plow
authors.forename: E F
authors.initials: EF
authors.lastname: Plow
mesh_terms: D001665:Binding Sites; D004730:Endothelium, Vascular / Q000166:cytology; D005732:Gangliosides / Q000494:pharmacology / Q000502:physiology; D006801:Humans; D017270:Lipoprotein(a) / Q000378:metabolism*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000473:pathology; D008562:Membrane Glycoproteins / Q000502:physiology; D009000:Monocytes / Q000378:metabolism; D009363:Neoplasm Proteins / Q000378:metabolism; D011485:Protein Binding / Q000187:drug effects; D011956:Receptors, Cell Surface / Q000378:metabolism*; D018110:Receptors, Lipoprotein / Q000378:metabolism; D055293:Receptors, Urokinase Plasminogen Activator; D014407:Tumor Cells, Cultured; D014471:Umbilical Veins
chemical_list: D005732:Gangliosides; D017270:Lipoprotein(a); D008562:Membrane Glycoproteins; D009363:Neoplasm Proteins; C524898:PLAUR protein, human; D011956:Receptors, Cell Surface; D018110:Receptors, Lipoprotein; D055293:Receptors, Urokinase Plasminogen Activator